Toripalimab

Neoadjuvant

ZHOU FANGJIANmonoclonal_antibodyPhase 3Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 89/ 100

Competitive context

7 Active assets in the Neoadjuvant cohort.

Asset / Sponsor	Phase	Rating
Axitinib ZHOU FANGJIAN	Phase 3	B
Irinotecan AbbVie	Phase 2	CCC
Mirvetuximab Soravtansine AbbVie	Phase 2	CCC
TRASTUZUMAB Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Phase 2	CCC
(+)-VINCRISTINE AbbVie	Phase 2	CCC

View all 11 →

Same molecule, other indications

Toripalimab is also rated in:

renal cell carcinomaDormant

BB

Indicative ·

67 / 100

extranodal nasal NK/T cell lymphomaDormant

BB

Indicative ·

66 / 100

ToripalimabDormant

BB

Indicative ·

66 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.